Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs VNET Group Inc (VNET) Price & Performance

Quest Diagnostics IncTrade
VNET Group IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs VNET Group Inc — how do they compare? Quest Diagnostics Inc trades at $237.07 (market cap $26.21B), while VNET Group Inc trades at $7.48 (market cap $2.14B). The key difference: Quest Diagnostics Inc is far larger — about 12.2× VNET Group Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.

DGXVNET
Market Cap
$26.21B$2.14B
Sector
HealthTechnology
52-Week High
$238.50$14.03
52-Week Low
$173.49$6.29
Enterprise Value
$31.97B$5.29B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

VNET Group Inc

VNET trades at $7.565, up 1.14% today, with a neutral technical signal. The stock shows mixed fundamentals: revenue grew to $9.95B in 2025, but net losses deepened to -$256.77M. Recent news highlights strategic investor entry and AI-driven data center demand, yet earnings misses and a class action settlement pose concerns. Cash flow remains positive from financing, but profitability metrics like ROE at -43.21% signal challenges.

Outlook is cautious; analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio of 50.18% heighten risk. Investors should weigh growth potential from AI expansion against execution and competitive pressures in China's data center market.

Returns comparison

Trailing returns across standard periods

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About VNET Group Inc

VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.

Read more on VNET